Oxford Immunotec Global PLC (OXFD) Shares Bought by First Light Asset Management LLC

First Light Asset Management LLC boosted its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 5.0% during the 1st quarter, Holdings Channel reports. The firm owned 626,585 shares of the company’s stock after acquiring an additional 29,807 shares during the quarter. Oxford Immunotec Global comprises approximately 1.7% of First Light Asset Management LLC’s investment portfolio, making the stock its 19th largest position. First Light Asset Management LLC’s holdings in Oxford Immunotec Global were worth $7,801,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Teachers Advisors LLC grew its position in Oxford Immunotec Global by 7.8% during the 4th quarter. Teachers Advisors LLC now owns 70,433 shares of the company’s stock worth $984,000 after purchasing an additional 5,075 shares during the last quarter. Wells Fargo & Company MN grew its position in Oxford Immunotec Global by 13.6% during the 4th quarter. Wells Fargo & Company MN now owns 44,004 shares of the company’s stock worth $614,000 after purchasing an additional 5,284 shares during the last quarter. New York State Common Retirement Fund grew its position in Oxford Immunotec Global by 11.0% during the 1st quarter. New York State Common Retirement Fund now owns 58,581 shares of the company’s stock worth $729,000 after purchasing an additional 5,800 shares during the last quarter. Bank of New York Mellon Corp grew its position in Oxford Immunotec Global by 9.4% during the 4th quarter. Bank of New York Mellon Corp now owns 69,740 shares of the company’s stock worth $975,000 after purchasing an additional 6,017 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Oxford Immunotec Global by 12.2% during the 4th quarter. Geode Capital Management LLC now owns 64,839 shares of the company’s stock worth $905,000 after purchasing an additional 7,033 shares during the last quarter. 91.75% of the stock is currently owned by institutional investors.

Several analysts have weighed in on OXFD shares. ValuEngine downgraded shares of Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Zacks Investment Research raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Friday, March 9th. BidaskClub downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Finally, BTIG Research set a $19.00 price objective on shares of Oxford Immunotec Global and gave the company a “buy” rating in a report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $17.40.

OXFD stock opened at $13.67 on Thursday. The firm has a market capitalization of $364.67 million, a PE ratio of -10.05 and a beta of -0.28. The company has a current ratio of 5.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global PLC has a 12 month low of $10.00 and a 12 month high of $19.51.

Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings data on Tuesday, May 1st. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. The business had revenue of $21.37 million for the quarter, compared to the consensus estimate of $20.96 million. Oxford Immunotec Global had a negative net margin of 34.13% and a negative return on equity of 43.51%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.36) EPS. research analysts expect that Oxford Immunotec Global PLC will post -0.98 EPS for the current fiscal year.

In other news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $12.77, for a total value of $38,310.00. Following the sale, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $229,860. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.61% of the stock is owned by corporate insiders.

Oxford Immunotec Global Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply